So, The Early Treatment Did Save Lives
Study published in Lancet demonstrates the evidence
Dear Kool Beens,
Thank you for joining me in the zoom sessions yesterday.
Following is the list of links and a brief summary of each study that we discussed.
Note before: super excited to share a new entry in DrBeen merch.
Entry is for long COVID and vaccine side-effects patients. It says: My Monocytes are Immortal. Ask Me Why!
Shop here: https://drbeen-medical-lectures.creator-spring.com/
Early Treatment Saves Lives
This randomized control trial provides evidence that the use of a combination of drugs within 48 hours of COVID-19 symptoms resulted in lower likelihood of clinical deterioration and was associated with rapid viral clearance. A must read study.
Reference:
Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial - eClinicalMedicine
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00096-8/fulltext#%20
New Preprint Study
The following study is a preprint by Dr. Bruce Patterson and his team. In this small study Dr. Patterson et. al find that the individuals suffering from long COVID like symptoms after vaccination have persistent spike protein S1, S2, and even a mutant S1 in their non-classical and intermediate (CD16+) monocytes. These monocytes have an affinity to bind with the blood vessel endothelium. Hence, vascular damage/inflammation and clotting will ensue.
Management approach they offer is CCR5 antagonists (like Maraviroc) and Statins to reduce the binding of CD16+ monocytes to endothelium.
Reference:
Persistence of S1 Spike Protein in CD16+ Monocytes up to 245 Days in SARS-CoV-2 Negative Post COVID-19 Vaccination Individuals with Post-Acute Sequalae of COVID-19 (PASC)-Like Symptoms | medRxiv
https://www.medrxiv.org/content/10.1101/2024.03.24.24304286v1
A Botched Ivermectin Study
This Ivermectin study demonstrates that Ivermectin has no meaningful contribution for COVID-19 management. My criticism of the study is the window of time for Ivermectin eligibility. They offered Ivermectin for patients with symptoms lasting for lesser than or equal to 14 days. Secondly, the drug is given only for three days instead of continuing till the recovery.
Still, the Ivermectin group had a mean 2.03 days reduction in time to self-reported recovery, while the mean duration of symptoms was 5 days. I think 5 days reduced to 3 days is pretty good. It demonstrates a better handle of the infection in our body. Still, the researchers declared it as no meaningful outcome.
Reference:
Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes - Journal of Infection
https://www.journalofinfection.com/article/S0163-4453(24)00064-1/fulltext
Bonus study:
Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans: Immunity
Related references:
Long COVID in the United States - PMC
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621843/
Long COVID: What We Know About Post-COVID Conditions | University of Maryland Medical System
CDC COVID Data Tracker: Home
Thank you, kind sir. Am excited to dive into the studies!
Many thanks for the links.Please may I have a link to the merchandise?
I wish to buy some.